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Properly planned and conducted randomized clinical trials remain susceptible to a lack of external validity. The
authors illustrate a model-based method to standardize observed trial results to a specified target population using
a seminal human immunodeficiency virus (HIV) treatment trial, and they provide Monte Carlo simulation evidence
supporting the method. The example trial enrolled 1,156 HIV-infected adult men and women in the United States in
1996, randomly assigned 577 to a highly active antiretroviral therapy and 579 to a largely ineffective combination
therapy, and followed participants for 52 weeks. The target population was US people infected with HIV in 2006, as
estimated by the Centers for Disease Control and Prevention. Results from the trial apply, albeit muted by 12%, to
the target population, under the assumption that the authors have measured and correctly modeled the determi-
nants of selection that reflect heterogeneity in the treatment effect. In simulations with a heterogeneous treatment
effect, a conventional intent-to-treat estimate was biased with poor confidence limit coverage, but the proposed
estimate was largely unbiased with appropriate confidence limit coverage. The proposed method standardizes
observed trial results to a specified target population and thereby provides information regarding the generaliz-
ability of trial results.
bias; bias (epidemiology); causal inference; external validity; generalizability; randomized trials; standardization
Abbreviations: ACTG, AIDS Clinical Trial Group; AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency
virus.
Properly planned and conducted randomized clinical tri-
als (henceforth referred to as trials) typically provide stron-
ger internal validity than observational study designs, such
as prospective cohort studies. Such trials accomplish height-
ened internal validity by ensuring that the conditions neces-
sary for proper inference are met. Specifically, trials ensure
consistency (1–3) and positivity (1, 4) by design and no
unmeasured confounding in expectation by randomization
(5, 6). Trials and cohort studies constrain the amount of
selection bias (7) due to dropout when near-complete patient
follow-up is attained. However, even such trials are suscep-
tible to a lack of external validity, or generalizability (8, 9),
as recently discussed (10–12). This susceptibility is a func-
tion of the extent to which trial participants do not represent
the target population. For an example of when trials might
selectively enroll from the target population, a recent study
(13) applied eligibility criteria from 32 human immunode-
ficiency virus (HIV) trials (largely funded by the National
Institutes of Health) to the Women’s Interagency HIV Study
(14) (the largest observational cohort of HIV-infected
women in the United States) and found that, across trials,
a median of 58% of women would have been eligible for
a given trial (range, 32.4%–100%).
In simple settings, trial results may be mapped to a target
population by using nonparametric direct standardization
(15, 16 (p. 49)). However, when there are many covariates,
or some covariates are continuous, direct standardization
will fail. Here, we illustrate a model-based method to stan-
dardize observed trial results to a specified target popula-
tion. Thereby, this method provides information regarding
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the generalizability of the trial results to the specified target
population. We apply the method to the AIDS (acquired
immunodeficiency syndrome) Clinical Trial Group (ACTG)
320 study (17), a landmark trial in HIV care that compared
a novel highly active antiretroviral therapy combination
(henceforth referred to as treatment) with a largely ineffec-
tive existing therapy combination (henceforth referred to as
control). In addition, we provide a limited Monte Carlo
simulation evaluation of the proposed method.
MATERIALS AND METHODS
Study population
Between January 1996 and January 1997, 1,156 patients
were recruited from 33 AIDS clinical trial units and 7 Na-
tional Hemophilia Foundation sites in the United States and
Puerto Rico (17). Eligible patients were 1) at least 16 years
of age, 2) HIV positive, 3) immunosuppressed (i.e., CD4
cell count <201 cells/mm3), 4) experienced with antiretro-
viral therapy (i.e., at least 3 months of prior zidovudine use),
and 5) able to care for themselves (i.e., Karnofsky perfor-
mance test score 70). Patients were excluded if they had
a week or more prior treatment with the nucleoside reverse
transcriptase inhibitor lamivudine or had any prior treatment
with protease inhibitors. Institutional review boards at each
of the participating institutions approved the study protocol,
and written informed consent was given by all study pa-
tients. The public-use ACTG 320 data set was used in the
present study and is available from the National Technical
Information Service (http://www.ntis.gov/).
At enrollment, patients were stratified by CD4 cell count
(i.e., 0–50 vs. 51–200 cells/mm3) and were randomly as-
signed with equal allocation to the treatment group (n ¼
577) or control group (n ¼ 579) (17). The therapy for the
control group consisted of the 2 nucleoside reverse tran-
scriptase inhibitors zidovudine and lamivudine, whereas
the therapy for the treatment group consisted of the same
2 nucleoside reverse transcriptase inhibitors plus the pro-
tease inhibitor indinavir. Characteristics of the 1,156 trial
patients are given in Table 1.
After randomization, patients were monitored with study
visits at weeks 4, 8, and 16, and every 8 weeks thereafter,
until a first occurrence of an AIDS-defining illness, death, or
the planned end of follow-up at 52 weeks. Fifty-one of 1,156
patients (4%) dropped out during follow-up. Of the 51 drop-
outs, 20 and 31 were in the treatment and control groups,
respectively. Ninety-six of 1,156 patients (8%) incurred
endpoints: 70 developed AIDS, and 26 died. Of the 96 end-
points, 33 were observed in the treatment group and 63 in
the control group. Noncompliance is ignored here; it was
previously described (17), and methods to account for non-
compliance (18, 19) revealed only a modest difference from
the hazard ratio obtained by intent-to-treat (20).
Target population
For illustrative purposes, we chose as the target popula-
tion the US estimate of the number of people infected with
HIV in 2006. This estimate was provided by the Centers
for Disease Control and Prevention (21, 22). HIV incidence
is not directly measured in the United States. However, in-
novative immunoassays are able to distinguish between re-
cent and established infections, allowing estimates of HIV
incidence (23–25). Information on newly diagnosed HIV
cases in 22 states was reported to the Centers for Disease
Control and Prevention for 2006. Remnant diagnostic serum
specimens from patients aged 13 years or older were tested
with an immunoassay to classify infections as recent or
established. HIV incidence was estimated by using a statis-
tical approach with adjustment for testing frequency and
was extrapolated to the United States (26). Characteristics
of the target population are also provided in Table 1. For this
target population, we did not have individual-level data but
did have the joint distribution (i.e., cross-classification) of
select characteristics, namely, sex, race, and age groups.
Statistical methods
We begin with a description of the notation we will use.
Uppercase letters denote random variables and lowercase
letters denote realizations of random variables, or constants.
Let Ti
* be Ti ^ Ci, where Ti and Ci are positive, real valued
times to the event of interest and right censoring, respec-
tively, for population member i ¼ 1 to n. We assume here
that right censoring is not informative, or formally that
f(T*) ¼ f(T* j T, C), where f(.j.) is the conditional density
function. Let Yi ¼ 1 denote the occurrence of the event of
interest (i.e., Ti
* ¼ Ti).
A population-level treatment effect is a comparison of
potential event times across different levels of a treatment,
Table 1. Characteristics of 1,156 HIV-infected Patients in the AIDS
Clinical Trial Group 320 Study in 1996–1997 Followed for 1 Year and
of the Estimated 54,220 HIV-infected Individuals in the United States
in 2006
Characteristica
Trial Patients US Population
No. % No. %
Age, years 38 (33, 44) NA
Age group, yearsb
13–29 106 09 18,500 34
30–39 515 45 16,740 31
40–49 388 34 13,370 25
50 147 13 5,610 10
Male sex 956 83 39,810 73
Race
White, non-Hispanic 623 54 19,580 36
Black, non-Hispanic 328 28 24,920 46
Hispanic 205 18 9,720 18
CD4 count (cells/mm3)c 75 (33, 137) NA
Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV,
human immunodeficiency virus; NA, not available.
a Values are expressed as median (quartiles) or percentage; per-
centages may not sum to 100 because of rounding.
b Youngest and oldest patients in the trial were aged 16 years and
75 years, respectively.
c CD4 cell count was missing for 1 trial patient.
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say X ¼ x. Formally, this is a comparison of the distribution
of T1i and T
0
i , where T
x is the potential event time under
treatment x. One way to quantify this comparison is to imag-
ine a Cox proportional hazards model (27) on the potential
event times as hTxðtÞ ¼ h0ðtÞ3expðaxÞ, where the estimand
exp(a) is the ratio of the hazard had the population been
exposed to the treatment to the hazard had the population
been exposed to the control.
Let Si¼ 1 denote selection from the target population into
the trial sample of
Pn
i¼1 Si patients. Where Si ¼ 1, let Xi ¼ 1
denote random assignment to the treatment group and 0 to
the control group. Typically, a treatment effect is estimated
in the trial sample, perhaps by using an analogous Cox
model, hTðtÞ ¼ h0ðtÞ3 expðbXiÞ, where estimation is by
Cox’s partial likelihood (28). The log hazard ratio in the
trial sample b will not generally equal the population esti-
mand a, except under conditions described in the Appendix.
A derivation of the bias in the trial sample estimate of the
population effect, defined as differences in means or pro-
portions, is also given in the Appendix. Next, we describe
the use of inverse probability-of-selection weights, which
are an extension of Horvitz-Thompson weights (29) and
have been used extensively in survey sampling (30–32),
for confounder control (33), and have been discussed in
the context of selection bias (7, 19, 34, 35) or response bias
in 2-phase studies (36).




PðSi ¼ 1j ZiÞ
; Si ¼ 1;
0; Si ¼ 0;
where P(.j.) is the conditional probability function. Let Z be
an n-by-p matrix of discrete or continuous variables that
describe the composition of the target population. For in-
stance, in the simplest form, say the target population may
be described by only a single binary characteristic such as
sex, Z¼ Zi ¼ 0 or 1. In our example, the target population is
described by the complete cross-classification of sex, race,
and age groups.
From the weight definition above, zero weights are given
to target population members who are not selected into
the trial sample, and real-valued positive weights are given
to members who are selected. For selected members, the
numerator of the weights, which is an estimate of the
marginal probability of being selected, implies that
EðWij Si ¼ 1Þ ¼ 1, where E(.j.) is the conditional expecta-
tion. The numerator is used to ensure that the weighted
sample remains the same size as the observed sample in
expectation. For selected members, the denominator of the
weights is an estimate of the probability of being selected
into the sample conditional on a vector of measured char-
acteristics Z. The weights Wi are therefore inversely pro-
portional to an estimate of the conditional probability of
being selected. On the basis of the findings given in the
Appendix, the collection of characteristics Z is chosen,
based on prior knowledge and data exploration, to include
factors 1) on which the trial sample differs from the target
population and 2) for which there is heterogeneity in the
effect of treatment on the outcome of interest.
The conditional probabilities for both the numerator and
denominator of the weights were obtained by using linear-
logistic regression models, specifically,
log
PðSi ¼ 1Þ
1 PðSi ¼ 1Þ
¼ d and log PðSi ¼ 1j ZiÞ
1 PðSi ¼ 1j ZiÞ
¼ Zi/;
where 1/[1 þ exp(d)] is the marginal probability of being
selected into the trial sample from the target population; Zi
includes a column of 1’s for the intercept; and exp(uk), for
k ¼ 1 to p, are the log odds ratios for being selected for each
component of the n-by-p covariate matrix Z. In the models
used for the ACTG 320 trial data, we included the charac-
teristics themselves, as well as product terms to account for
the joint distribution.
An inverse probability-of-selection-weighted Cox pro-










where Rk(ti) ¼ 1 if patient k is at risk for the event at the
event time for patient i, namely ti. The resultant log hazard
ratio, c, provides a consistent, asymptotically normal esti-
mate of the population treatment effect a under the assump-
tion that the model for the denominator of the selection
weight includes all characteristics that both 1) differ be-
tween trial sample and target population and 2) demonstrate
heterogeneity in the treatment effect. A proof of the consis-
tency of the proposed method for the special case of the
difference in means or proportions is provided in the Ap-
pendix. Throughout, hazard ratios are used to measure the
strength of association, 95% confidence limits are used to
measure precision, robust variances (37–39) are used in
conjunction with weighted Cox models (40), and confidence
limit ratios are used to compare precision across estimates.
The confidence limit ratio is simply the ratio of the upper to
the lower confidence limit. The proportional hazards as-
sumption appeared reasonable in these data under the orig-
inal intent-to-treat analysis (P for heterogeneity ¼ 0.263)
and the proposed weighted analysis (P for heterogeneity ¼
0.211).
RESULTS
The intent-to-treat analysis of the ACTG 320 trial found
a hazard of AIDS or death of 0.51 (95% confidence limits:
0.33, 0.77) for the 577 people randomly assigned to the
treatment group relative to the 579 randomly assigned to
the control group. In the trial, older age was associated with
higher incidence of AIDS or death (P for trend ¼ 0.0315);
compared with the age group 13–29 years, the hazard ratios
for the age groups 30–39, 40–49, and 50 were 1.33 (95%
confidence limits: 0.56, 3.15), 1.43 (95% confidence limits:
0.59, 3.44), and 2.32 (95% confidence limits: 0.92, 5.82),
respectively. However, neither male sex (hazard ratio ¼
0.98, 95% confidence limits: 0.55, 1.73) nor race was
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strongly associated with incident AIDS or death (compared
with the hazard ratio for whites, the hazard ratio for black
non-Hispanics was 0.77 (95% confidence limits: 0.46, 1.28)
and for Hispanics was 1.19 (95% confidence limits: 0.71,
2.00)).
Table 2 presents adjusted odds ratios for selection into the
trial from the estimated US population infected in 2006. For
presentation in Table 2, we omitted product terms between
components of Z, but such terms are included for construc-
tion of W, as noted above. Males, those of white race or
Hispanic ethnicity (compared with black race), or those
older than age 30 years were more likely to be selected into
the trial.
Table 3 presents the hazard ratios and 95% confidence
limits applicable to the trial patients as well as for the target
population. As expected, based on the results in Table 2 and
the age-stratified trial results in Table 3, when accounting
only for the difference in age between the trial sample and
target population, the hazard ratio was markedly muted from
0.51 to 0.68 because the trial selected for older population
members, for whom the treatment effect appeared stronger.
Similar results can be obtained by use of direct standardi-
zation when the dimension of Z is low. For instance, if the
age-stratified hazard ratios (i.e., 1.87, 0.21, 0.84, and 0.59;
Table 3) are log-transformed and combined by using the
target population frequency distribution (i.e., 0.34, 0.31,
0.25, and 0.10; Table 1), the antilog of the direct standard-
ized estimate is 0.69, which is similar to our model-based
standardized estimate of 0.68. Furthermore, when we ac-
counted only for the difference in sex between the trial
sample and target population, the hazard ratio was slightly
weaker because (as shown in Tables 2 and 3) the trial se-
lected for males and the treatment effect appeared stronger
in males. Finally, when we accounted only for the difference
in race/ethnicity between the trial sample and target popu-
lation, the hazard ratio was stronger because the trial se-
lected against blacks and the treatment effect appeared
stronger in blacks.
All weighted estimates have wider confidence intervals
than those in the trial, expressed in Table 3 as confidence
limit ratios. The wider interval widths reflect the difference
between the trial sample and target population. In fact, for
the 3 single-attribute-weighted estimates in Table 3, the
ranking of the confidence limit ratios accords with the dis-
tance between the hazard ratio for the trial sample and the
hazard ratio for the target population.
When we simultaneously accounted for differences in
age, sex, and race/ethnicity between the trial sample and
target population, the hazard ratio was weakened from
0.51 to 0.57. This somewhat muted effect is apparent in
Figure 1, which presents the complement of the Kaplan-
Meier survival curves for the trial and the analogous curves
(41) for the target population. Moreover, precision is some-
what decreased when inference is generalized to the target
population, as is evident by the confidence limit ratios in
Table 3.
Table 2. Odds Ratios and 95% Confidence Limits for Selection Into
the AIDS Clinical Trial Group 320 Study in 1996–1997 From the
Estimated US Population Infected With HIV in 2006
Characteristica Odds Ratio 95% CL
Age group, yearsb
13–29 1
30–39 4.93 4.02, 6.12
40–49 4.75 3.82, 5.89
50 4.29 3.34, 5.52
Male sex 1.51 1.29, 1.77
Race
White, non-Hispanic 1
Black, non-Hispanic 0.51 0.45, 0.59
Hispanic 1.53 1.28, 1.83
Abbreviations: AIDS, acquired immunodeficiency syndrome; CL,
confidence limit; HIV, human immunodeficiency virus.
a Odds ratios were adjusted for the variables listed in the table.
b Youngest and oldest patients in the trial were aged 16 years and
75 years, respectively.
Table 3. Hazard Ratios and 95% Confidence Limits for Incident
AIDS or Death Within 1 Year for Patients in the AIDS Clinical Trial
Group 320 Study in 1996–1997 and for the Population of Individuals
Infected With HIV in 2006, United States
Hazard Ratio 95% CL CL Ratio
Trial results
Intent-to-treata 0.51 0.33, 0.77 2.33
Age-group stratified,
yearsb,c
13–29 1.87 0.34, 10.2
30–39 0.21 0.09, 0.48
40–49 0.84 0.41, 1.70
50 0.59 0.24, 1.45
Sex stratifiedd
Male 0.47 0.29, 0.74
Female 0.76 0.28, 2.10
Race stratifiede
White, non-Hispanic 0.59 0.34, 1.01
Black, non-Hispanic 0.30 0.11, 0.83
Hispanic 0.54 0.22, 1.36
Population results
Age weighted 0.68 0.39, 1.17 3.00
Sex weighted 0.53 0.34, 0.82 2.41
Race weighted 0.46 0.29, 0.72 2.48
Age-sex-race weighted 0.57 0.33, 1.00 3.03
Abbreviations: AIDS, acquired immunodeficiency syndrome;
CL, confidence limit; HIV, human immunodeficiency virus.
a The age-group-adjusted hazard ratio was 0.50 (95% CL: 0.33,
0.77).
b P for homogeneity ¼ 0.0348.
c Youngest and oldest patients in the trial were aged 16 years and
75 years, respectively.
d P for homogeneity ¼ 0.3930.
e P for homogeneity ¼ 0.5396.
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In the next section, we describe a simulation experiment.




We compare the proposed method with conventional in-
tent-to-treat estimates of the hazard ratio in a setting that
mimics the ACTG 320 trial. To compare the approaches,
we calculated bias, computed as the estimated log hazard
ratio minus the true log hazard ratio (described below); stan-
dard error, computed as the average of the estimated standard
errors; Monte Carlo standard error, computed as the standard
deviation of the estimated log hazard ratios; root mean
squared error, computed as the square root of the squared
bias plus the squared Monte Carlo standard error; and confi-
dence limit coverage, computed as the proportion of times the
confidence limit contains the true hazard ratio (estimated with
the standard error, not the Monte Carlo standard error). Sim-
ulation results are subject to Monte Carlo error; on the basis
of the 10,000 simulations, the 95% confidence limit coverage
estimates have a simulation standard error of about 0.2%.
A simulated data record comprises a value for Z, X, T, S;
we drew i ¼ 1 to 10,000 simulated population member rec-
ords for each of 10,000 simulation data sets. First, a Ber-
noulli random variable was generated with marginal
probability of 0.5 for a single demographic characteristic
Z. Second, a Bernoulli random variable was generated with
marginal probability 0.5 for treatment X. Third, a lognormal
random variable was generated conditional on the realized














The parameters {a0, a1, a2, r} were chosen to represent 3
scenarios. To inform these simulations, the parameters of
a lognormal model (which was the best-fitting parametric
model of those explored for the control group in the ACTG
320 trial) were a0 ¼ 8.585 (standard error, 0.4340) and r ¼
2.709 (standard error, 0.2885). First, we chose a0 ¼ 8.585,
a1 ¼ 0, a2 ¼ 0, and r ¼ 2.709 such that the expectation of
the true hazard ratio was 1, and we term this scenario ‘‘no
effect.’’ Second, we chose a0 ¼ 8.585, a1 ¼ 1.23, a2 ¼ 0,
and r ¼ 2.709 such that the expectation of the true hazard
ratio was approximately 0.5, as in the ACTG 320 trial; we
term this scenario ‘‘homogeneous effect.’’ Third, we chose
a0 ¼ 8.585, a1 ¼ 0.75, a2 ¼ 2.10, and r ¼ 2.709 such that
the expectation of the true hazard ratio was again approxi-
mately 0.5, as in ACTG 320, and we term this scenario
‘‘heterogeneous effect.’’
The lognormal-distributed times were administratively
censored at a fixed time such that, in expectation, we ob-
served approximately 100 events per study, as in the ACTG
320 trial. In all cases, the reference for calculation of bias
and confidence limit coverage was the true hazard ratio
obtained in the complete target population. Last, a Bernoulli
random variable was generated for selection into the trial S,
conditional on the realized value of the demographic char-
acteristic Z, as 1=f1þ exp½  b0  b1Zig, with b1 set at
log(4) to reflect the size of selection effects observed in
the ACTG 320 trial for age groups and b0 chosen to main-
tain a marginal probability of 0.1. We calculated both naı̈ve
and robust (40) variance estimates for the weighted models.
Simulation results
Across all simulations, the estimated stabilized weights
(in the selected samples) had a mean of 1.00 (standard de-
viation, ffi0.66) with minimum and maximum values of
about 0.6 and 2.75, respectively.
In Table 4, for the no-effect and homogeneous-effect sce-
narios, both the conventional intent-to-treat estimate of the
hazard ratio and the weighted estimate of the hazard ratio
provide unbiased estimates with appropriate confidence
limit coverage. In such cases, the conventional hazard ratio
Figure 1. Complement of the Kaplan-Meier survival curves, acquired immunodeficiency syndrome (AIDS) Clinical Trial Group 320 Study, 1996–
1997, United States. A) intent-to-treat; B) selection probability weighted. Solid lines represent patients randomly assigned to the control group;
dashed lines represent patients randomly assigned to the treatment group.
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is more precise than the weighted hazard ratio, as evidenced
by a 1.2-fold relative root mean squared error (0.227/0.189,
Table 4).
For the heterogeneous-effect scenario in Table 4, the con-
ventional estimate is severely biased, leading to abysmal
confidence limit coverage. However, the weighted estimate
is largely unbiased with appropriate confidence limit cover-
age. Use of naı̈ve standard errors for the weighted estimate
led to undercoverage of the confidence limits (coverage of
0.902, 0.906, and 0.871 for the 3 scenarios, respectively),
but the use of robust standard errors raised the coverage to
nominal levels, as shown in Table 4. Similar simulations
were conducted for the odds ratio, with equally supportive
results (data not shown).
DISCUSSION
We illustrated a method to generalize inferences from
a randomized clinical trial to a specified target population
using inverse probability-of-selection weights. In the ACTG
320 trial, the method demonstrated that inferences apply,
albeit muted by 12%, to estimates of the US population
infected in 2006, under the assumption that we have mea-
sured and correctly modeled the determinants of selection
that reflect heterogeneity in the etiologic effect. The pro-
posed method is supported by a limited Monte Carlo
experiment.
The approach proposed here is one of model-based stan-
dardization (16, 42–44). Perhaps Lane and Nelder stated the
idea most succinctly, in its simpler one-sample form, ‘‘con-
sider a survey of the incidence of disease in cattle, where
proportions affected are recorded for different age groups in
different regions. After the selection and fitting of a suitable
model, the fitted proportions can be combined with popula-
tion frequencies (assuming these to be known) and summed
over regions, to give a prediction of the total incidence for
the whole country’’ (42, p. 614). Next, we provide some
important caveats.
First, akin to the assumptions of no unmeasured con-
founders and no unmeasured informative censoring, in prac-
tice we will only at best be able to identify and measure
a subset of the characteristics that lead to effect heteroge-
neity. Therefore, the proposed estimator will only approxi-
mate the etiologic effect in a defined target population to the
extent that we capture said characteristics and specify them
appropriately in the selection model. The proposed ap-
proach, or any that we can imagine, will need to have in-
formation on the joint distribution of the modifying
characteristics in the target population and have these char-
acteristics measured in the trial. In some settings, this may
be difficult. In our case, we did not have individual-level
data on the target population and instead used the summary
statistics in the target population to construct a pseudo-
population with the appropriate joint distribution of sex,
race, and age groups. The method could easily be extended
to incorporate individual-level data on the population if it
were available, as illustrated by Stuart et al. (45).
Furthermore, in our example, the CD4 cell count differs
between the target population and the trial sample. Based on
an understanding of the natural history of HIV infection, the
target population of recently infected people has relatively
normal immune function. However, the trial sample is im-
mune suppressed, as shown in Table 1. If the treatment
effect is heterogeneous with respect to immune function,
then we would be missing an important characteristic. In-
deed, the related issue of when to start HIV therapies with
respect to CD4 cell count is of prime clinical concern (46–
48) but beyond our current scope. Moreover, even with
a correct set of measured characteristics, one must correctly
specify the selection model to maintain valid inferences; this
requirement is relaxed if the selection model is saturated, as
in our example. By ‘‘saturated’’ we mean that there is a pa-
rameter for every cell in the cross-classified data table such
that data are not smoothed (of course, data reflecting con-
tinuous factors, such as age, are categorized). Exploration of
this central assumption of measuring the relevant heteroge-
neity factors requires more attention. However, it seems that
even a partially corrected mapping of the trial result to
a target population is a step forward.
A second caveat is that we concentrated on mapping an
observed intent-to-treat result estimated in a trial to a spec-
ified target population defined by baseline characteristics
that are measured in the trial and are known in the target
population. Here, we did not attempt to account for post-
randomization variables (12), but such steps may be impor-
tant especially when the intent-to-treat estimate is subject to
nontrivial bias due to noncompliance (49, 50).
Third, we ignored uncertainty in the distribution of char-
acteristics in the target population. Information for the target
population used here was based on a large, nationally rep-
resentative sample. However, in settings where the distribu-
tion of characteristics in the target population is subject to
a large amount of random error, the proposed method should
be extended to account for this uncertainty. This is a topic
for future research.
Table 4. Simulation Results for 10,000 Samples per Scenario Each












No effect 0.003 0.188 0.189 0.189 0.955
Homogeneous
effect
0.014 0.232 0.235 0.235 0.945
Heterogeneous
effect




No effect 0.003 0.225 0.227 0.227 0.948
Homogeneous
effect
0.020 0.275 0.280 0.279 0.948
Heterogeneous
effect
0.000 0.246 0.246 0.246 0.955
Abbreviations: CL, confidence limit; MSE, mean squared error;
SE, standard error.
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Fourth, the information observed for the trial patients is
optimal for standardization to the same population structure,
so the reduction in precision observed when generalizing
from a trial to a target population will be an increasing
function of the ‘‘distance’’ between the trial patients and
target population. At one extreme, where the trial patients
and target population are completely divergent, there is no
information for estimating the effect in the target popula-
tion, and one must rely on extrapolation.
Last, we illustrated methods here using the Cox propor-
tional hazards model (27) because the hazard ratio is a cen-
tral measure of association in randomized clinical trials.
However, the hazard ratio is intrinsically susceptible to se-
lection bias, and perhaps survival curves or relative survival
times provide more clear measures of causal effects (51–
53).
In conclusion, the proposed method standardizes ob-
served trial results to a specified target population. There-
fore, the proposed method provides direct information
regarding generalizability of the trial results to the speci-
fied target population. The approach may prove useful in
projecting the effects of interventions in populations that
may differ in composition from those studied in random-
ized clinical trials. Moreover, the present approach can
itself be generalized to nonrandomized settings, which is
a topic we intend to discuss in future work.
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APPENDIX
In this Appendix, we provide a proof of the asymptotic
consistency of the proposed method for the case of the mean
or proportion; results extend to the hazard but are not proven
here. As a preliminary step, we derive the bias in the con-
ventional intent-to-treat estimator.








and b ¼ E






Y0j S ¼ 1

, where E(.j.) is the conditional expectation
taken with respect to an enumerated target population in-
dexed by i ¼ 1 to n, Yxi is the potential outcome that would
have occurred for person i under treatment X ¼ x, and
S 2 f0; 1g is an indicator of pretreatment selection into
a sample of the target population. Although public health
practitioners and clinicians may be interested in the popu-
lation average treatment effect a, a conventional intent-to-
treat comparison of groups randomized to treatment X ¼ x
from the sample provides an estimate of b.
If a 6¼ E





Y0j Z ¼ z

and PðS ¼ 1Þ 6¼
PðS ¼ 1j Z ¼ zÞ for a pretreatment covariate Z, where
P(.j.) is a conditional probability taken with respect to the
target population, then, except in circumstances of chance
balancing cancellations, a 6¼ b. Informally, the expectation
of the difference in potential outcomes in the target popula-
tion differs from the expectation of the difference in poten-
tial outcomes in an observed sample of the target population
defined by S ¼ 1 when there is heterogeneity in the causal
effect of treatment X due to Z and the sample selection
mechanism depends on Z.
If we limit our setting only in that Z 2 f0; 1g, then
the bias of b, as a measure of a, is bxz3

PðZ ¼ 1Þ
PðS ¼ 1Þ 3h
PðS ¼ 1 j Z ¼ 1Þ  PðS ¼ 1Þ
io
, where bxz is a coefficient
representing the heterogeneity in the X effect due to Z in the
outcome model EðYiÞ ¼ b0 þ bxXi þ bxzXiZi. A main effect
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for Z can be added to the outcome model without inducing
any problem other than unnecessarily complicating the
steps below. Therefore, the bias depends positively on the
effect heterogeneity, the prevalence of the heterogeneity
characteristic Z, the proportion of the target population not
sampled, and the strength of the association between the
heterogeneity characteristic and selection. In particular,
there is no bias if there is no heterogeneity in the X effect
due to Z, no one in the population has the heterogeneity
characteristic (i.e., PðZ ¼ 1Þ ¼ 0), the ‘‘sample’’ consists
of the entire population (i.e., PðS ¼ 1Þ ¼ 1), or sample
selection does not depend on Z (i.e., PðS ¼ 1j Z ¼ zÞ ¼









¼ ½b0 þ bx þ bxzPðZ ¼ 1Þ  b0


































¼ b0 þ bx þ bxz 1PN
i¼1 SiXi
PN
i¼1 SiXiZi  b0
¼ bx þ bxzPðZ ¼ 1j S ¼ 1;X ¼ 1Þ;




Y0i by the consistency assump-
tion (2). Then,
b a ¼ ½bx þ bxzPðZ ¼ 1j S ¼ 1;X ¼ 1Þ  ½bx þ bxzPðZ ¼ 1Þ
¼ bx þ bxzPðZ ¼ 1j S ¼ 1;X ¼ 1Þ  bx  bxzPðZ ¼ 1Þ
¼ bxz 3 ½PðZ ¼ 1j S ¼ 1;X ¼ 1Þ  PðZ ¼ 1Þ
¼ bxz 3 ½PðS¼1jZ¼1ÞPðZ¼1ÞPðS¼1Þ  PðZ ¼ 1Þ
¼ bxz 3 ½PðS¼1jZ¼1ÞPðZ¼1ÞPðS¼1Þ  PðZ¼1ÞPðS¼1ÞPðS¼1Þ 
¼ bxz 3 ½PðS¼1jZ¼1ÞPðZ¼1ÞPðZ¼1ÞPðS¼1ÞPðS¼1Þ 
¼ bxz 3 ½PðZ¼1ÞPðS¼1Þ½PðS ¼ 1 j Z ¼ 1Þ  PðS ¼ 1Þ;
where, in the fourth line of the above derivation,
PðZ ¼ 1 j S ¼ 1;X ¼ 1Þ ¼ PðS ¼ 1j Z ¼ 1ÞPðZ ¼ 1Þ
PðS ¼ 1Þ by
Bayes’ rule. We have also assumed the independence con-
dition EðXj S; Z; YxÞ ¼ EðXÞ. This condition says that treat-
ment assignment is independent of sample selection, the
covariate, and the potential outcomes. This ignorable treat-
ment mechanism would be granted in expectation by ran-
dom treatment assignment that does not depend on S or Z.
This assumption may be relaxed for stratified randomization
or nonrandomized studies (where E(X) may depend on Z),
but that leads to a more complex formula for the bias.
Assume further that PðS ¼ 1j Z ¼ z; YxÞ ¼
PðS ¼ 1j Z ¼ zÞ or, in words, that we have an ignorable
sample selection mechanism, conditional on Z, and
that PðS ¼ 1j Z ¼ zÞ > 0 for all individuals. Such a mech-
anism would be granted in expectation by Z-stratified
random sampling from the target population, where
every individual has a positive probability of being
selected.










, where wðZÞ ¼
PðS ¼ 1j Z ¼ zÞ and eð;Þ ¼ PðX ¼ xÞ. Then, c is an inverse
probability-of-selection-weighted expectation of the differ-
ence in potential outcomes in an observed sample of the
target population, and c ¼ a under the above-stated assump-
tions. A proof builds on the work of Horvitz and Thompson
(29) and extends that of Lunceford and Davidian (54) to









IðS ¼ 1ÞIðX ¼ 1ÞY
























where I(.) is the indicator function. Steps are given by the
law of conditional expectations, the consistency as-
sumption, rearrangement, Z-conditional ignorable selec-
tion and ignorable treatment mechanisms, and the
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